There's another abiraterone phase III trial but in chemo/biologic naive CRPC patients, who failed anti-androgen therapy, also under an SPA. Primary endpoints are OS and PFS but JNJ can file based on PFS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.